• Philippe Menasché.
• Department of Cardiovascular Surgery, Hôpital Européen Georges Pompidou, University Paris Descartes, Sorbonne Paris Cité; and INSERM U 970, Paris, France. Electronic address: philippe.menasche@aphp.fr.
• J. Thorac. Cardiovasc. Surg. 2016 Aug 1; 152 (2): 345-9.

AbstractThere is accumulating evidence that the cardioprotective effects of stem cells are predominantly mediated by the release of a blend of factors, possibly clustered into extracellular vesicles, which harness endogenous repair pathways. The clinical translation of this concept requires the identification of the cell-secreted signaling biomolecules and an appropriate transfer method. The study by Wei and colleagues has addressed these 2 requirements by showing that the epicardial delivery of a collagen patch loaded with the cardiokine follistatin-like 1 improved left ventricular function in animal models of myocardial infarction. Beyond the choice of the factor and its vehicle, these data may open a new therapeutic path whereby the functionalization of biomaterials by bioactive compounds could successfully substitute for the current cell transplantation-based strategy.Copyright © 2016 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

31 keywords...

hide…